in

VRd Plus Isatuximab Improves Outcomes

Source link : https://www.newshealth.biz/health-news/vrd-plus-isatuximab-improves-outcomes/

The addition of an anti-CD38 monoclonal antibody to the standard first-line combination treatment significantly improved outcomes in newly diagnosed, transplant-ineligible patients with multiple myeloma (MM), according to an interim analysis of an open-label, randomized, phase 3 trial. Patients who took isatuximab (Sarclisa) plus bortezomib, lenalidomide, and dexamethasone (VRd) reached higher estimated progression-free survival at a […]

Author : News Health

Publish date : 2024-06-12 06:28:58

Copyright for syndicated content belongs to the linked Source.

Jeanne Brunfaut : “Les producteurs de movies savent que c’est de leur responsabilité d’éviter ces dérapages”

US Open greens will lead to ‘war of attrition’